- Home
- Aid by Department
- Department of Health and Social Care
Department of Health and Social Care
Fleming Fund - Independent Evaluation
UK - Department of Health and Social Care (DHSC)
The independent evaluation will assess how far the outputs of the portfolio of Fleming Fund country and regional grants, and the Fleming Fellowships contribute to the outcomes and impact identified by the Department of Health and Social Care (DHSC). Six specific evaluation questions were agreed during the inception phase for the evaluation. In answering these six questions, the evaluation intends to meet two objectives: 1. In 2019, the evaluation will generate learning to inform course correction and adaptation in the present phase of support; 2. In late 2020, the evaluation’s focus will shift to providing an independent summative judgement of the Fund’s results and achievements. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - Country and Regional Grants and Fellowships Programme
UK - Department of Health and Social Care (DHSC)
The Fleming Fund helps low- and middle-income countries to fight antimicrobial resistance. A management agent has been appointed to deliver: country grants 24 low- and middle-income countries, regional grants in West Africa, East and Southern Africa, South Asia and South East Asia, and a global fellowships programme. These initiatives aim to improve laboratory capacity and diagnosis as well as data and surveillance of antimicrobial resistance (AMR). Through the country and regional grants and the fellowships programme the Fleming Fund will: build laboratory capacity for diagnosis; collect data on drug resistance, drug quality, drug use and the burden of disease associated with AMR; enable the sharing of data relevant to AMR locally, regionally, and internationally; encourage the application of data to promote the rational use of antimicrobials; shape a sustainable system for AMR surveillance and data sharing; and increase national leadership in addressing AMR. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund
UK - Department of Health and Social Care (DHSC)
The Fleming Fund is a £265m commitment by the UK Government to support low- and middle-income countries to tackle antimicrobial resistance (AMR) through improving surveillance capacity. Information about individual Fleming Fund projects and contracts can be found under the "child activities" linked to this activity. The Fleming Fund aims to: 1. support the development of National Action Plans for AMR; 2. develop and support the implementation of protocols and guidance for AMR surveillance and antimicrobial use; 3. build sustainable laboratory capacity for AMR sensitivity testing and diagnosis; 4. build sustainable drug resistance surveillance capacity and networks; 5. enable the sharing of drug resistance data locally, regionally and nationally; 6. facilitate the increased use of drug resistance data to monitor and address resistance as it evolves; and 7. advocate for the application of data to promote the rationale use of antimicrobials for human health, animal health and agriculture. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - GRAM Global Burden of Disease Project
UK - Department of Health and Social Care (DHSC)
Grant to University of Oxford/Institute of Health Metrics and Evaluation to collect, synthesise and visualise data on the burden of disease associated with anitmicrobial resistance (AMR), quantify the problem and promote policy attention and resource allocation to tackle the issue. To collect data on the burden of disease associated with antimicrobial resistance (AMR) in low- and middle-income countries (LMICs), synthesise this data, and ensure that AMR is included within the Global Burden of Disease study. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - Contribution to the International Reference Centre for Antimicrobial Resistance
UK - Department of Health and Social Care (DHSC)
The Fleming Fund contribution to a UK draw-down service for technical assistance, training and quality assurance for low and middle income countries to support antimicrobial resistance (AMR) surveillance system building across all one-health sectors. The objectives of the reference centre are to: 1. Develop capacity of low- and middle-income countries (LMICs) for surveillance of AMR and antimicrobial use (AMU) through residential AMR training workshops, country visits to partners to offer training, provision of proficiency testing schemes; 2. Strengthen governance related to AMU and AMR by providing expert advice on new or emerging resistances that present a threat to animal or public health, providing expert advice on how to bench-mark capability and the authorisation of antibiotics and providing verification testing at our UK laboratories; 3. Promote good agricultural practices and prudent use of antimicrobials by providing advice and support for the adaptation and implementation of alternatives to antibiotics; and 4. Raise awareness of AMR by publishing and contributing to expert reports and peer-reviewed scientific manuscripts. Projects funded through the Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in AMR Diagnostic Tools with FIND
UK - Department of Health and Social Care (DHSC)
FIND is a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support FIND’s work to enhance the impact of diagnostic tools for antimicrobial resistance (AMR), to support improved AMR surveillance and antibiotic stewardship. This work has two areas of focus: 1) to develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access of data; and 2) to develop a new diagnostic technologies for drug-resistant gonorrhea, which will enable improved diagnosis and therefore use of new antibiotics. Projects funded through GAMRIF will primarily benefit people in low- and middle-income countries, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with BactiVac
UK - Department of Health and Social Care (DHSC)
Vaccine Innovation with BactiVac is a partnership between the UK government and the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for AMR in humans and animals. The UK government has invested up to £1 million over one year into BactiVac, which is one of 5 networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research & Development. This is co-funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships, and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for antimicrobial resistance (AMR) for the benefit of people in low- and middle-income countries (LMICs). Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Fleming Fund - Multilateral Grant to Food and Agriculture Organisation (FAO)
UK - Department of Health and Social Care (DHSC)
Contribution to the Food and Agriculture Organisation (FAO) to increase public and political awareness of antimicrobial resistance (AMR) and support countries with AMR National Action Plans. The objectives of the Fleming Fund grant with FAO are to: 1. support development and implementation of AMR National Action Plans in 12 low- and middle-income countries (LMICs) in sub-Saharan Africa and South and South-east Asia; 2. strengthen regulatory frameworks; 3. increase societal awareness and understanding of AMR; 4. develop good practices in food and agriculture sectors, and ensure these are able to be implemented in target countries; and 5. strengthen the coordination across WHO, FAO and OIE in supporting the One Health agenda globally, and more specifically in LMICs. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - Multilateral Grant to World Health Organization (WHO)
UK - Department of Health and Social Care (DHSC)
Contribution to the World Health Organization (WHO) to support countries with antimicrobial resistance (AMR) National Action Plans and development of global protocols for collection of AMR data. The objectives of the Fleming Fund grant with WHO are to: 1. support countries to develop National Action Plans aligned with our regional focus in Sub-Saharan Africa, South and South-East Asia; 2. develop a One Health surveillance protocol on antimicrobial resistance focused on Escherichia coli (E. coli); 3. develop, pilot and roll out methods for antibiotic consumption and use monitoring; 4. Develop and support countries to implement of a new classification of antibiotics within the Essential Medicines List (EML) and the AWaRe categorisation to encourage rational use of antibiotics; 5. to support a deeper understanding of SF antimicrobials and their impact upon AMR; and 6. strengthen the coordination across WHO, FAO and OIE in supporting the One Health agenda globally, and more specifically in low- and middle-income countries (LMICs) Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
UK Public Health Rapid Support Team - Rapid investigation and response
UK - Department of Health and Social Care (DHSC)
"Created in 2016, the UK-PHRST is the primary arm of Her Majesty’s Government to provide and coordinate the UK’s public health response to outbreaks in LMICs. The UK-PHRST is a unique collaboration between Public Health England and the London School of Hygiene and Tropical Medicine with input from a number of academic partners. The UK-PHRST’s remit covers outbreak response, research, and capacity building, as components of its integrated triple mandate: • Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance (ODA), with the aim of stopping a public health threat from becoming a broader health emergency • Conduct research to generate an evidence base for best practice in epidemic preparedness and response • Build capacity for improved and rapid national response to disease outbreaks in LMICs and contribute to supporting implementation of IHR at the request of national governments or international stakeholders such as WHO. The UK-PHRST rapidly deploys a standing team of multidisciplinary public health professionals and researchers as required in countries that are a priority for the UK’s ODA programme. The UK-PHRST full-time Core Deployable Team consists of specialists in epidemiology, laboratory microbiology, infection prevention and control, clinical case management and clinical research, social science, data management and logistical support who are available to deploy within 48 of an approved request. Reservists and Field Epidemiology Training Programme (FETP) Fellows complement this team, providing surge capacity and specialist expertise when needed. The UK-PHRST is financed through UK Official Development Assistance (ODA) funding through the Department of Health and Social Care. The UK-PHRST Director is the accountable person to the UK Government, through PHE, for delivery of the UK-PHRST objectives." "The UK-Public Health Rapid Support Team is a key international partner in epidemic disease response. We partner with low- and-middle income countries to respond to infectious disease outbreaks before they can develop into global health emergencies. We work closely with international organisations, partner country governments and non-governmental organisations to: - Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance, with the aim of stopping a public health threat from becoming a broader health emergency - Conduct research to generate an evidence base for best practice in epidemic preparedness and response - Strengthen capacity for improved national response to disease outbreaks in LMICs We are an innovative partnership between the UK Health Security Agency and the London School of Hygiene & Tropical Medicine, funded with UK aid by the UK Department of Health and Social Care." The UK Public Health Rapid Support Team (UK -PHRST) has the following main objectives: 1) Within ODA eligible countries to support the rapid investigation and response to disease outbreaks at source, with the aim of stopping a public health threat becoming a health emergency. 2) Conduct rigorous research to aid epidemic preparedness and response and improve future response. 3) Generate an evidence base for best practice in disease outbreak interventions within ODA eligible countries. 4) Train a cadre of public health reservists for the UK -PHRST who can be rapidly deployed to respond to disease outbreaks. 5) Build capacity in-country for an improved and rapid national response to disease outbreaks and contribute to supporting implementation of the International Health Regulations (IHR).
International Health Regulations (IHR) Strengthening project
UK - Department of Health and Social Care (DHSC)
The DHSC ODA-funded International Health Regulations Strengthening Project (IHR-S) provides peer to peer technical expertise through the UK Health Security Agency (UKHSA) to support public health partners to prepare, prevent, detect and respond to global health threats and increase compliance with the WHO International Health Regulations (IHR 2005). Compliance with IHR (2005) is fundamental as infectious disease outbreaks are expected to become more frequent in the future and preparedness is necessary to reduce health threats both internationally and within the UK. Lack of compliance to meet IHR (2005) requirements places countries under greater risk from disease outbreaks and other health emergencies, and has potentially wider implications on a global scale, as evidenced by the spread of Covid-19. IHR (2005) includes 13 technical areas such as surveillance, laboratories and points of entry as focal points to support countries to prevent, detect and respond to health threats. The IHR Strengthening Project has three key aims: to build technical capability, to strengthen leadership, systems and workforces, as well as to develop sustainable public health systems. IHR-S works bilaterally with four priority partner countries and three regions [including Nigeria, Pakistan, Ethiopia, Zambia, Africa (primarily through Africa CDC), the Eastern Mediterranean and Indo Pacific regions]. Over the course of this project the UK will work closely with the World Health Organization (WHO) to help it fulfil its leadership role in implementing the IHR and in responding to global public health emergencies. The project will work intimately with national governments, development partners and with regional and sub-regional agencies to deliver its support. This support will be coordinated with support from other donors, ensuring it adds value and is sustainable, identifies and responds to gaps, complements support from others and aligns behind nationally identified priorities. Implementation of UK support will be led by Public Health England, but may include contracting and working through UN agencies where appropriate and where this will maximise value for money.
Fleming Fund - Multilateral Grant to World Organisation for Animal Health (WOAH)
UK - Department of Health and Social Care (DHSC)
Contributions to the World Organisation for Animal Health (WOAH ) to improve regulatory frameworks and monitor targeting veterinary medicines. The objectives of the Fleming Fund grant with WOAH are to: 1. improve recognition of the critical importance of tacking antimicrobial resistance (AMR) and raised awareness among veterinary health professionals and the general public; 2. agree WOAH standards on AMR and progress towards implementation of these standards in low- and middle-income countries (LMICs); 3. support member states to collect and report data on the use of antimicrobial agents in animals; 4. improve regulatory frameworks targeting veterinary medicines including antimicrobials; and 5. strengthen the coordination across WHO, FAO and WOAH in supporting the One Health agenda globally, and more specifically in LMICs. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - Civil society engagement through South Centre grant
UK - Department of Health and Social Care (DHSC)
Through a grant to the South Centre the Fleming Fund is seeking to increase understanding of the challenges around antimicrobial resistance (AMR) and advocate for action among governments, civil society organisations and networks in low- and middle-income countries (LMICs). The grant to the South Centre will aim to 1. support positive developments in global processes of AMR and commitments to actions on addressing AMR; 2. assist developing countries to participate positively in the global processes on AMR and to have a sense of ownership of this agenda; 3. build the knowledge base and capacity of LMICs to understand the nature and seriousness of the AMR crisis and to take policy measures and actions nationally to address this crisis; and 4. strengthen the capability of civil society groups to build awareness and take actions on AMR issues. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - Commonwealth Partnerships for Antimicrobial Stewardship Scheme
UK - Department of Health and Social Care (DHSC)
A partnership programme to improve antimicrobial stewardship across Zambia, Tanzania, Ghana, Uganda, Sierra Leone, Kenya, Malawi and Nigeria. The partnerships leverage the expertise of UK health institutions and technical experts to strengthen the capacity of the national health workforce and institutions to address predefined antimicrobial resistance (AMR) challenges. The project aims to 1. Develop partnerships between NHS Trusts (hospitals) and clinics/hospitals in low- and middle-income commonwealth countries. 2. Share UK expertise abroad as well as bring skills and knowledge back to NHS Trusts. 3. Create focused partnerships on the theme of AMR, that includes activity on; Antimicrobial stewardship, including surveillance (AMS); Infection prevention control and Antimicrobial pharmacy expertise and capacity; and 4. More generally improve the knowledge, skills and empowerment of healthcare professionals and pharmacists in partner institutions. Improving the healthcare workforce to ultimately contribute to a strengthened health system. Projects funded through the Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater
UK Public Health Rapid Support Team - Research
UK - Department of Health and Social Care (DHSC)
"Created in 2016, the UK-PHRST is the primary arm of Her Majesty’s Government to provide and coordinate the UK’s public health response to outbreaks in LMICs. The UK-PHRST is a unique collaboration between Public Health England and the London School of Hygiene and Tropical Medicine with input from a number of academic partners. The UK-PHRST’s remit covers outbreak response, research, and capacity building, as components of its integrated triple mandate: • Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance (ODA), with the aim of stopping a public health threat from becoming a broader health emergency • Conduct research to generate an evidence base for best practice in epidemic preparedness and response • Build capacity for improved and rapid national response to disease outbreaks in LMICs and contribute to supporting implementation of IHR at the request of national governments or international stakeholders such as WHO. The UK-PHRST rapidly deploys a standing team of multidisciplinary public health professionals and researchers as required in countries that are a priority for the UK’s ODA programme. The UK-PHRST full-time Core Deployable Team consists of specialists in epidemiology, laboratory microbiology, infection prevention and control, clinical case management and clinical research, social science, data management and logistical support who are available to deploy within 48 of an approved request. Reservists and Field Epidemiology Training Programme (FETP) Fellows complement this team, providing surge capacity and specialist expertise when needed. The UK-PHRST is financed through UK Official Development Assistance (ODA) funding through the Department of Health and Social Care. The UK-PHRST Director is the accountable person to the UK Government, through PHE, for delivery of the UK-PHRST objectives." The UK Public Health Rapid Support Team (UK-PHRST) has the following main objectives: 1) Within ODA eligible countries to support the rapid investigation and response to disease outbreaks at source, with the aim of stopping a public health threat becoming a health emergency. 2) Conduct rigorous research to aid epidemic preparedness and response and improve future response. 3) Generate an evidence base for best practice in disease outbreak interventions within ODA eligible countries. 4) Train a cadre of public health reservists for the UK-PHRST who can be rapidly deployed to respond to disease outbreaks. 5) Build capacity in-country for an improved and rapid national response to disease outbreaks and contribute to supporting implementation of the International Health Regulations (IHR).
UK Vaccine Network - BactiVac Network
UK - Department of Health and Social Care (DHSC)
The BactiVac Network aims to accelerate the development of vaccines against bacterial infections aimed at reducing antimicrobial use in humans and animals, relevant to low- and middle-income countries (LMICs). An investment of up to £1,400,000 will fund projects in two rounds of funding that support the development of vaccines that can prevent and/or minimise the emergence and transmission of antimicrobial resistance (AMR). Partnerships of at least two organisations are a requirement of funding, with at least one partner based in the UK, and partnerships with LMIC researchers are prioritised. This grant will directly benefit people in LMICs, both from the research and the established partnerships which will then be able to apply for further substantive follow-on funding in the field. The primary aim of the funding is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and is expected. Funding will also support other Network activities which promote collaboration across the membership, particularly for members based in LMICs.
UK Vaccine Network - Vaccine Manufacturing Research Hubs Competition 2
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is collaborating with EPSRC (a nondepartmental public body principally funded through the Science Budget by the Department of Science, Innovation and Technology) in running the Vaccine Manufacturing Research Hubs competition. EPSRC has considerable expertise in running competitions in this nature. The Vaccine Manufacturing Research Hubs competition will be open to all eligible research organisations that can demonstrate that their work would contribute towards Vaccine Manufacturing Research. Successful projects will be awarded a research grant from EPSRC, mostly funded by DHSC.
UK Vaccine Network - UK Health Security Agency
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is making up to £3,100,000 available to the UK Health Security Agency (UKHSA) under the provisions of the International Development Act of 2002 to deliver a programme of seven projects that will advance vaccine development for diseases of epidemic potential for the benefit of people in low- and middle-income countries (LMICs). The programme will be wholly funded by DHSC through UK aid. The seven projects are: 1. CL4 Live Virus Neutralisation Tests; 2. Development of PNA Capability for Priority Pathogens; 3. Multiplex pAn-Virus Inhibition (MAVI) assays; 4. Preclinical model expansion for the assessment of cross-protective vaccines candidates against henipaviruses; 5. Development of GMP LassaVacc: Progression towards clinical trials; 6. Development of an X-ray inactivated whole virus vaccine for Zika and efficacy testing in an established rodent model; and 7. Advancement of a cost-effective MVA based Hantavirus vaccine (HantaVacc).
UK Vaccine Network - Vaccines for epidemic diseases: readiness for clinical development and regulatory submission competition
UK - Department of Health and Social Care (DHSC)
The Project is a Small Business Research Initiative (SBRI), Official Development Assistance (ODA) competition funded by the Department of Health and Social Care (DHSC). The aim of the competition is to further invest in vaccines and vaccine technologies to address the 12 priority diseases (including Disease X) identified by the UK Vaccine Network. Proposals can address any part of the pre-clinical, non-clinical, manufacturing, or clinical pathway, within a 1-year time frame, making technology ready to be progressed further along the developmental pathway. This is a managed programme on behalf of DHSC. UKRI-Innovate UK are providing a fully managed end to end service. The call goes live on 4th October 2021. The SBRI contracts are required to be in place and live by 31 March 2022. Beneficiary Projects funded through this competition are required to primarily benefit ODA eligible countries, as per ODA policy.
UK Vaccine Network - Vaccine development for diseases with epidemic potential
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. DHSC is engaging Innovate UK (an Executive Non-Departmental Public Body established by the Higher Education and Research Act 2017) to run the Vaccine development for diseases with epidemic potential competition. Innovate UK are responsible for the delivery and management of this work on behalf of DHSC. DHSC is making up to £25,000,000 (twenty-five million pounds) available to Innovate UK under the provisions of the International Development Act of 2002 to run the Vaccine development for diseases with epidemic potential competition and fund the Successful Project(s).
Advanced filters
To search for Programmes in a specific time period, please enter the start and end dates.